Pilot study of a protocol to administer inhaled nitric oxide to treat severe acute submassive pulmonary embolism

Jeffrey Kline, Jackeline Hernandez, John S. Garrett, Alan E. Jones

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: Inhaled nitric oxide has been reported to benefit patients with acute pulmonary embolism (PE). To date, all published literature has derived from case reports or case series conducted without a structured protocol. Here we report the results of a phase I trial with a predefined clinical protocol to treat patients with CT-demonstrated, submassive PE and moderate to severe dyspnoea. Methods: Patients were recruited from the emergency department of an academic teaching hospital. Informed consent and the entire treatment protocol was administered by a study physician. Nitric oxide was administered using a commercial device (Inovent) and a custom-made non-rebreathing face mask. The NO concentration was increased at 1 ppm/min (parts per million) until a maximum of 25 ppm and continued for 120 min and then weaned at 1 ppm/min. Dyspnoea was assessed with the Borg score, oxygenation by pulse oximetry, and haemodynamic status by shock index (HR/SBP). Results: Eight patients were enrolled. All patients tolerated the entire protocol without adverse events, and all had decreased numerical Borg score by >50%. The changes from baseline to 155 min were as follows: Borg score 7.5±2.5 to 2.3±1.9 (p=0.06, Signed rank test), SaO2% 93±5 to 97±3 and shock index 1.0±0.11 to 0.86±0.09. No patient experienced worsening during weaning. Conclusions: Inhaled NO reduced dyspnoea without adverse events in eight patients with severe submassive PE. This protocol can serve as the basis for a phase II trial or for a compassionate use protocol.

Original languageEnglish
Pages (from-to)459-462
Number of pages4
JournalEmergency Medicine Journal
Volume31
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Pulmonary Embolism
Nitric Oxide
Dyspnea
Clinical Protocols
Shock
Compassionate Use Trials
Oximetry
Masks
Weaning
Informed Consent
Teaching Hospitals
Hospital Emergency Service
Hemodynamics
Physicians
Equipment and Supplies

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Emergency Medicine
  • Medicine(all)

Cite this

Pilot study of a protocol to administer inhaled nitric oxide to treat severe acute submassive pulmonary embolism. / Kline, Jeffrey; Hernandez, Jackeline; Garrett, John S.; Jones, Alan E.

In: Emergency Medicine Journal, Vol. 31, No. 6, 2014, p. 459-462.

Research output: Contribution to journalArticle

Kline, Jeffrey ; Hernandez, Jackeline ; Garrett, John S. ; Jones, Alan E. / Pilot study of a protocol to administer inhaled nitric oxide to treat severe acute submassive pulmonary embolism. In: Emergency Medicine Journal. 2014 ; Vol. 31, No. 6. pp. 459-462.
@article{946efb980665401e84e378af86b9978e,
title = "Pilot study of a protocol to administer inhaled nitric oxide to treat severe acute submassive pulmonary embolism",
abstract = "Objective: Inhaled nitric oxide has been reported to benefit patients with acute pulmonary embolism (PE). To date, all published literature has derived from case reports or case series conducted without a structured protocol. Here we report the results of a phase I trial with a predefined clinical protocol to treat patients with CT-demonstrated, submassive PE and moderate to severe dyspnoea. Methods: Patients were recruited from the emergency department of an academic teaching hospital. Informed consent and the entire treatment protocol was administered by a study physician. Nitric oxide was administered using a commercial device (Inovent) and a custom-made non-rebreathing face mask. The NO concentration was increased at 1 ppm/min (parts per million) until a maximum of 25 ppm and continued for 120 min and then weaned at 1 ppm/min. Dyspnoea was assessed with the Borg score, oxygenation by pulse oximetry, and haemodynamic status by shock index (HR/SBP). Results: Eight patients were enrolled. All patients tolerated the entire protocol without adverse events, and all had decreased numerical Borg score by >50{\%}. The changes from baseline to 155 min were as follows: Borg score 7.5±2.5 to 2.3±1.9 (p=0.06, Signed rank test), SaO2{\%} 93±5 to 97±3 and shock index 1.0±0.11 to 0.86±0.09. No patient experienced worsening during weaning. Conclusions: Inhaled NO reduced dyspnoea without adverse events in eight patients with severe submassive PE. This protocol can serve as the basis for a phase II trial or for a compassionate use protocol.",
author = "Jeffrey Kline and Jackeline Hernandez and Garrett, {John S.} and Jones, {Alan E.}",
year = "2014",
doi = "10.1136/emermed-2013-202426",
language = "English",
volume = "31",
pages = "459--462",
journal = "Emergency Medicine Journal",
issn = "1472-0205",
publisher = "BMJ Publishing Group",
number = "6",

}

TY - JOUR

T1 - Pilot study of a protocol to administer inhaled nitric oxide to treat severe acute submassive pulmonary embolism

AU - Kline, Jeffrey

AU - Hernandez, Jackeline

AU - Garrett, John S.

AU - Jones, Alan E.

PY - 2014

Y1 - 2014

N2 - Objective: Inhaled nitric oxide has been reported to benefit patients with acute pulmonary embolism (PE). To date, all published literature has derived from case reports or case series conducted without a structured protocol. Here we report the results of a phase I trial with a predefined clinical protocol to treat patients with CT-demonstrated, submassive PE and moderate to severe dyspnoea. Methods: Patients were recruited from the emergency department of an academic teaching hospital. Informed consent and the entire treatment protocol was administered by a study physician. Nitric oxide was administered using a commercial device (Inovent) and a custom-made non-rebreathing face mask. The NO concentration was increased at 1 ppm/min (parts per million) until a maximum of 25 ppm and continued for 120 min and then weaned at 1 ppm/min. Dyspnoea was assessed with the Borg score, oxygenation by pulse oximetry, and haemodynamic status by shock index (HR/SBP). Results: Eight patients were enrolled. All patients tolerated the entire protocol without adverse events, and all had decreased numerical Borg score by >50%. The changes from baseline to 155 min were as follows: Borg score 7.5±2.5 to 2.3±1.9 (p=0.06, Signed rank test), SaO2% 93±5 to 97±3 and shock index 1.0±0.11 to 0.86±0.09. No patient experienced worsening during weaning. Conclusions: Inhaled NO reduced dyspnoea without adverse events in eight patients with severe submassive PE. This protocol can serve as the basis for a phase II trial or for a compassionate use protocol.

AB - Objective: Inhaled nitric oxide has been reported to benefit patients with acute pulmonary embolism (PE). To date, all published literature has derived from case reports or case series conducted without a structured protocol. Here we report the results of a phase I trial with a predefined clinical protocol to treat patients with CT-demonstrated, submassive PE and moderate to severe dyspnoea. Methods: Patients were recruited from the emergency department of an academic teaching hospital. Informed consent and the entire treatment protocol was administered by a study physician. Nitric oxide was administered using a commercial device (Inovent) and a custom-made non-rebreathing face mask. The NO concentration was increased at 1 ppm/min (parts per million) until a maximum of 25 ppm and continued for 120 min and then weaned at 1 ppm/min. Dyspnoea was assessed with the Borg score, oxygenation by pulse oximetry, and haemodynamic status by shock index (HR/SBP). Results: Eight patients were enrolled. All patients tolerated the entire protocol without adverse events, and all had decreased numerical Borg score by >50%. The changes from baseline to 155 min were as follows: Borg score 7.5±2.5 to 2.3±1.9 (p=0.06, Signed rank test), SaO2% 93±5 to 97±3 and shock index 1.0±0.11 to 0.86±0.09. No patient experienced worsening during weaning. Conclusions: Inhaled NO reduced dyspnoea without adverse events in eight patients with severe submassive PE. This protocol can serve as the basis for a phase II trial or for a compassionate use protocol.

UR - http://www.scopus.com/inward/record.url?scp=84901687292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901687292&partnerID=8YFLogxK

U2 - 10.1136/emermed-2013-202426

DO - 10.1136/emermed-2013-202426

M3 - Article

C2 - 23585574

AN - SCOPUS:84901687292

VL - 31

SP - 459

EP - 462

JO - Emergency Medicine Journal

JF - Emergency Medicine Journal

SN - 1472-0205

IS - 6

ER -